These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 23138287)

  • 21. [Health cost and imaging].
    Ducou le Pointe H
    Arch Pediatr; 2006 Jun; 13(6):591. PubMed ID: 16697569
    [No Abstract]   [Full Text] [Related]  

  • 22. [Analysis of the progressivity of Brazilian Unified National Health System (SUS) financing].
    Ugá MA; Santos IS
    Cad Saude Publica; 2006 Aug; 22(8):1597-609. PubMed ID: 16832531
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The dilemma of Proposition 13: panel discussion.
    Am J Orthopsychiatry; 1980 Apr; 50(2):225-38. PubMed ID: 7361872
    [No Abstract]   [Full Text] [Related]  

  • 24. Granting you success.
    Beylin D; Chrisman CJ; Weingarten M
    Nat Biotechnol; 2011 Jul; 29(7):567-70. PubMed ID: 21874663
    [No Abstract]   [Full Text] [Related]  

  • 25. Benefits of biotech clusters questioned.
    Sheridan C
    Nat Biotechnol; 2003 Nov; 21(11):1258-9. PubMed ID: 14595343
    [No Abstract]   [Full Text] [Related]  

  • 26. French research minister targets IT and biotech.
    McCabe H
    Nature; 2000 May; 405(6783):106. PubMed ID: 10821237
    [No Abstract]   [Full Text] [Related]  

  • 27. Biotech firms jump on SARS bandwagon.
    Basu P
    Nat Biotechnol; 2003 Jul; 21(7):720. PubMed ID: 12833076
    [No Abstract]   [Full Text] [Related]  

  • 28. [Medicoeconomic results of the pediatric unit at Le Havre hospital].
    Le Luyer B; Daire I; Le Roux P; Briquet E
    Arch Pediatr; 2006 Jun; 13(6):588-91. PubMed ID: 16697566
    [No Abstract]   [Full Text] [Related]  

  • 29. BIO 2006 Annual International Convention. The expanding biotech industry of France.
    Zarkowska T
    IDrugs; 2006 Jun; 9(6):383-5. PubMed ID: 16752302
    [No Abstract]   [Full Text] [Related]  

  • 30. Congress punts on SBIR reauthorization.
    Thiel K
    Nat Biotechnol; 2009 Dec; 27(12):1065-6. PubMed ID: 20010562
    [No Abstract]   [Full Text] [Related]  

  • 31. Support for biotechnology.
    Hambleton P
    J Chem Technol Biotechnol; 1990; 47(2):171-7. PubMed ID: 1366406
    [No Abstract]   [Full Text] [Related]  

  • 32. Impossible fixes.
    Nat Biotechnol; 2010 Feb; 28(2):103. PubMed ID: 20139925
    [No Abstract]   [Full Text] [Related]  

  • 33. How the EU can fund your company.
    Gilbert N
    Nat Biotechnol; 2007 Jan; 25(1):21-4. PubMed ID: 17294566
    [No Abstract]   [Full Text] [Related]  

  • 34. Biotech parks proliferate, despite concerns over sustainability.
    Jia H; Jayaraman KS; Orellana C
    Nat Biotechnol; 2003 Nov; 21(11):1259-60. PubMed ID: 14595344
    [No Abstract]   [Full Text] [Related]  

  • 35. Increasing number of companies found ineligible for SBIR funding.
    Bouchie A
    Nat Biotechnol; 2003 Oct; 21(10):1121-2. PubMed ID: 14520384
    [No Abstract]   [Full Text] [Related]  

  • 36. The perils of subsidiarity.
    Nat Biotechnol; 2004 Dec; 22(12):1483. PubMed ID: 15583638
    [No Abstract]   [Full Text] [Related]  

  • 37. Little science, big bucks.
    DeFrancesco L
    Nat Biotechnol; 2003 Oct; 21(10):1127-9. PubMed ID: 14520387
    [No Abstract]   [Full Text] [Related]  

  • 38. Biotech round the world: focus on Canada.
    Biotechnol J; 2008 Jul; 3(7):848-51. PubMed ID: 18624341
    [No Abstract]   [Full Text] [Related]  

  • 39. Council tax precept failed to cover cost of NLW.
    Nurs Older People; 2016 Aug; 28(7):9. PubMed ID: 27573947
    [TBL] [Abstract][Full Text] [Related]  

  • 40. New Zealand launches biotech seed fund.
    Griggs K
    Nat Biotechnol; 2004 Apr; 22(4):480-1. PubMed ID: 15085809
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.